NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce ...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback